Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Diphenhydramine vs ALAVERT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.
Allergic rhinitis,Urticaria,Pruritus,Insomnia (OTC sleep aid),Motion sickness,Parkinsonism (off-label for extrapyramidal symptoms)
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.
Terminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Terminal elimination half-life of loratadine is 8–11 hours; its active metabolite desloratadine has a half-life of 17–24 hours. The longer half-life of desloratadine contributes to sustained antihistaminic effect.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2C9, and CYP2C19; undergoes N-demethylation and N-oxidation; first-pass metabolism is extensive.
Primarily metabolized by CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine.
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
Approximately 40% of the dose is excreted in urine (25% as unchanged drug and 15% as active metabolite desloratadine) and 40% in feces (as metabolites).
98-99% bound, primarily to albumin.
Loratadine: 97–99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound.
Vd 3-5 L/kg (wide distribution, high tissue binding).
Loratadine: approximately 120 L (1.7 L/kg for a 70 kg adult), indicating extensive tissue distribution. Desloratadine: 30–40 L/kg.
Oral: 50-70% (first-pass metabolism). IM: 100% (assumed). IV: 100%.
Oral bioavailability is low (approximately 40–50%) due to extensive first-pass metabolism. Food increases bioavailability by 40% but does not affect clinical efficacy.
No specific dose adjustment for GFR. Use with caution in severe renal impairment (Cr Cl <10 m L/min) due to potential accumulation; consider reducing dose or extending interval.
For GFR 30-50 m L/min: 10 mg every 48 hours. For GFR <30 m L/min or on dialysis: avoid use or adjust to 10 mg every 72 hours with close monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider 25% of usual dose or avoid.
Child-Pugh A: no adjustment. Child-Pugh B: 10 mg every 48 hours. Child-Pugh C: avoid use or 10 mg every 72 hours.
Children 2-5 years: 6.25 mg orally every 4-6 hours (max 37.5 mg/day). Children 6-11 years: 12.5-25 mg orally every 4-6 hours (max 150 mg/day). Children ≥12 years: 25-50 mg orally every 4-6 hours (max 300 mg/day).
Age 6-11 years: 5 mg orally once daily; for PRN use, 5 mg every 4-6 hours, max 15 mg/day. Age ≥12 years: 10 mg orally once daily or 10 mg every 4-6 hours PRN, max 24 mg/day.
Elderly patients (>65 years): initially 25 mg orally at bedtime, increase if needed; maximum 50 mg/day. Avoid as first-line antihistamine due to anticholinergic adverse effects (confusion, falls).
Initiate at 5 mg orally once daily; may increase to 10 mg once daily if tolerated and needed. Caution due to increased risk of anticholinergic effects and impaired renal function.
Not recommended for use in neonates or premature infants due to potential association with sudden infant death syndrome (SIDS) and paradoxical CNS excitation.
None.
Causes significant sedation, impairing ability to drive or operate machinery; anticholinergic effects may exacerbate narrow-angle glaucoma, urinary retention, hyperthyroidism, hypertension, and prostatic hypertrophy; avoid concurrent use with alcohol or other CNS depressants.
Avoid use in patients with severe hepatic impairment,Renal impairment may require dose adjustment,Caution in elderly patients due to increased anticholinergic sensitivity
Hypersensitivity to diphenhydramine or any antihistamine; acute asthma attack; concurrent MAOI therapy; breastfeeding (large doses may decrease milk production and cause infant sedation); narrow-angle glaucoma (absolute); urinary retention (absolute).
Hypersensitivity to loratadine or any component of the formulation
No significant food interactions. Grapefruit juice may theoretically inhibit CYP2D6 metabolism, but clinical relevance is minimal. Avoid alcohol due to additive CNS depression.
Grapefruit juice may slightly increase loratadine absorption but not clinically significant. No specific dietary restrictions. Alcohol may increase CNS depression.
First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second trimester: No known risk. Third trimester: Near term, high doses may cause oxytocin-like effects; once-daily antihistamine effect with minimal fetal risk. Avoid use during late third trimester due to potential for uterine hyperstimulation.
ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on available human data, first trimester exposure does not show increased risk of major malformations. Second and third trimester risks are not established, but adverse fetal outcomes are unlikely given lack of placental transfer concerns.
Breastfeeding safety: Compatible, but caution advised due to potential for sedation and irritability in the infant. M/P ratio: Not clinically established; oral bioavailability is low but infant exposure is minimal at typical maternal doses. Avoid use in nursing mothers if alternative antihistamines with better safety profiles are available.
Loratadine is excreted into human breast milk. The milk-to-plasma ratio is approximately 1.17, with low relative infant dose (<2% of maternal weight-adjusted dose). Considered compatible with breastfeeding, but monitor infant for drowsiness or irritability. Caution in premature infants or those with renal impairment.
No specific dosing adjustments recommended based on pregnancy-induced pharmacokinetic changes. However, due to increased volume of distribution and altered hepatic metabolism in pregnancy, some clinicians may use lower starting doses for efficacy. Monitor for excessive sedation and adjust accordingly.
No dose adjustment is routinely recommended for pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, hepatic metabolism) are not significant enough to require dose changes for loratadine. Standard adult dose (10 mg once daily) can be used.
Diphenhydramine is a first-generation antihistamine with strong anticholinergic effects; avoid in elderly due to increased risk of confusion, falls, and urinary retention. Rapid IV administration can cause hypotension and arrhythmias; give slow IV push. Use with caution in patients with glaucoma, prostate hypertrophy, or asthma. Onset of sedation within 30-60 minutes; useful for acute dystonias (e.g., from antipsychotics) at 25-50 mg IM/IV. Not recommended for children <2 years due to risk of respiratory depression.
Alavert (loratadine) is a non-sedating antihistamine with minimal anticholinergic effects. Onset of action is within 1-3 hours; peak effect at 8-12 hours. Useful for chronic urticaria and allergic rhinitis. Does not cause significant QTc prolongation. Avoid in severe hepatic impairment (Child-Pugh C) without dose adjustment.
Do not drive or operate heavy machinery until you know how this drug affects you, as it causes drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and fall risk.,Dry mouth, blurred vision, and constipation are common; drink water and use sugar-free gum for dry mouth.,If you have difficulty urinating or eye pain, stop the medication and seek medical help.,Do not exceed recommended dose; overdose can cause seizures, hallucinations, or serious heart problems.,Take with food if stomach upset occurs, but avoid grapefruit juice as it may affect drug metabolism.
Take once daily at the same time, with or without food.,Do not exceed recommended dose to avoid side effects.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not use for acute asthma attacks or lower respiratory symptoms.,Store at room temperature away from moisture and heat.,Notify your doctor if symptoms persist or worsen.
"Diphenhydramine, a first-generation antihistamine with significant central nervous system (CNS) depressant effects, and clonazepam, a benzodiazepine that enhances GABA-A receptor activity, produce additive CNS depression when co-administered. This synergistic effect increases the risk of excessive sedation, psychomotor impairment, respiratory depression, and potential for falls, especially in elderly patients. Clinically, patients may experience profound drowsiness, confusion, ataxia, and impaired cognitive and motor function, which can lead to accidents or worsen sleep-disordered breathing."
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Cevimeline, a muscarinic agonist used for xerostomia, can inhibit the metabolism of diphenhydramine by competitively blocking cytochrome P450 (CYP) 2D6 and 3A4 enzymes. This results in reduced clearance of diphenhydramine, leading to elevated plasma concentrations and increased risk of anticholinergic side effects such as sedation, confusion, dry mouth, blurred vision, and urinary retention. Clinically, patients may experience enhanced and prolonged central nervous system depression and anticholinergic toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Diphenhydramine vs ALAVERT, answered by our medical review team.
Diphenhydramine is a Antihistamine that works by Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.. ALAVERT is a Second-generation Antihistamine that works by Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Diphenhydramine and ALAVERT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Diphenhydramine is: 25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).. The standard adult dose of ALAVERT is: 10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Diphenhydramine and ALAVERT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Diphenhydramine is classified as Category C. First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second t. ALAVERT is classified as Category C. ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on ava. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.